Please assess the completion status of the following clinical trial:

Trial Title: Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, ≥ 18 years of age~* HCV Genotype 1 or 4 who previously failed treatment with Peginterferon alfa-2a or peginterferon alfa-2b and Ribavirin (P/R), classified as previous null and partial responders based on previous therapy~* HCV RNA ≥ 10,000 IU/mL~* Seronegative for Human immunodeficiency virus (HIV) and Hepatitis B surface antigen (HBsAg)~* Subjects with compensated cirrhosis are permitted (compensated cirrhotics are capped at approximately 25% of treated population)~Exclusion Criteria:~* Prior treatment of HCV with HCV direct acting antiviral (DAA)~* Evidence of a medical condition contributing to chronic liver disease other than HCV~* Evidence of decompensated liver disease including, but not limited to, a history or presence of ascites, bleeding varices, or hepatic encephalopathy~* Diagnosed or suspected hepatocellular carcinoma or other malignancies~* Uncontrolled diabetes or hypertension~* Total bilirubin ≥ 34 μmol/L (or ≥ 2 mg/dL) unless subject has a documented history of Gilbert's disease~* Alanine aminotransferase (ALT) ≥ 5x Upper limit of normal (ULN)~* Albumin \< 3.5 g/dL (35 g/L)~* Alpha Fetoprotein (AFP) \> 100 ng/mL (\>82.6 IU/mL) or ≥ 50 and ≤ 100 ng/mL requires a liver ultrasound and subjects with findings suspicious of Hepatocellular carcinoma (HCC) are excluded~* Absolute neutrophil count (ANC) \< 1.5 x 1000,000,000 cells/L (\< 1.2 x 1000,000,000 cells/L for Black/African-Americans)~* Platelets \< 90 x 1000,000,000 cells/L~* Hemoglobin \< 12 g/dL for females or \< 13 g/dL for males~* Any criteria that would exclude the subject from receiving P/R

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QUAD: Asunaprevir+Daclatasvir+Peg-interferon Alfa-2a+Ribavirin (Type: EXPERIMENTAL): Asunaprevir: Capsule, Oral, 100 mg, Twice daily, 24 weeks~Daclatasvir: Tablet, Oral, 60 mg, Once daily, 24 weeks~Peg-interferon Alfa-2a: Injection, subcutaneous (SC), 180 mcg/0.5 mL, Once weekly, 24 weeks~Ribavirin: Tablet, Oral, 1000 mg/1200 mg (total daily dose), 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).